These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 6505735)

  • 1. Case report 294. Diagnosis: dialysis osteomalacia with response to desferrioxamine therapy.
    Xipell JM; Ham KN; Brown DJ; Dawborn JK
    Skeletal Radiol; 1984; 12(4):298-302. PubMed ID: 6505735
    [No Abstract]   [Full Text] [Related]  

  • 2. Aluminum-related osteomalacia: clinical and histological improvement following treatment with desferrioxamine (DFO).
    Rapoport J; Chaimovitz C; Abulfil A; Mostovlavsky M; Gazit D; Bab I
    Isr J Med Sci; 1987 Dec; 23(12):1242-6. PubMed ID: 3440748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in bone histology after treatment with desferrioxamine.
    Ott SM; Andress DL; Nebeker HG; Milliner DS; Maloney NA; Coburn JW; Sherrard DJ
    Kidney Int Suppl; 1986 Feb; 18():S108-13. PubMed ID: 3457986
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of dialysis osteomalacia with desferrioxamine.
    Brown DJ; Dawborn JK; Ham KN; Xipell JM
    Lancet; 1982 Aug; 2(8294):343-5. PubMed ID: 6124756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Desferrioxamine and osteomalacia.
    Mudde AH; Roodvoets AP
    Lancet; 1982 Sep; 2(8298):608. PubMed ID: 6125750
    [No Abstract]   [Full Text] [Related]  

  • 6. Do serum aluminum levels reflect underlying skeletal aluminum accumulation and bone histology before or after chelation by deferoxamine?
    Hodsman AB; Hood SA; Brown P; Cordy PE
    J Lab Clin Med; 1985 Dec; 106(6):674-81. PubMed ID: 4067379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The natural course of dialysis osteomalacia.
    Llach F; Felsenfeld AJ; Coleman MD; Keveney JJ; Pederson JA; Medlock TR
    Kidney Int Suppl; 1986 Feb; 18():S74-9. PubMed ID: 3458001
    [No Abstract]   [Full Text] [Related]  

  • 8. [The general principles of the diagnosis of dialysis osteomalacia by the results of the histomorphometry of spongy bone].
    Novikov AI; Ivanov AE; Golovniak IE; Baeva LB; Levitskiĭ ER
    Ter Arkh; 1991; 63(12):107-10. PubMed ID: 1803585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deferoxamine-induced bone changes in haemodialysis patients: a histomorphometric study.
    Charhon SA; Chavassieux P; Boivin G; Parisien M; Chapuy MC; Traeger J; Meunier PJ
    Clin Sci (Lond); 1987 Aug; 73(2):227-34. PubMed ID: 3652627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteomalacia and bone disease arising from aluminum.
    Coburn JW; Norris KC; Nebeker HG
    Semin Nephrol; 1986 Mar; 6(1):68-89. PubMed ID: 3110896
    [No Abstract]   [Full Text] [Related]  

  • 11. Persistence of dialysis osteomalacia despite treatment with 24R,25-dihydroxycholecalciferol.
    Phelps KR; Einhorn TA; Vigorita VJ; Jones G; Lundin AP
    Nephron; 1989; 51(2):197-206. PubMed ID: 2783766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clearance of aluminum by hemodialysis: effect of desferrioxamine.
    Milliner DS; Hercz G; Miller JH; Shinaberger JH; Nissenson AR; Coburn JW
    Kidney Int Suppl; 1986 Feb; 18():S100-3. PubMed ID: 3457984
    [No Abstract]   [Full Text] [Related]  

  • 13. Desferrioxamine therapy in hemodialysis patients with aluminum-associated bone disease.
    Felsenfeld AJ; Rodriguez M; Coleman M; Ross D; Llach F
    Kidney Int; 1989 Jun; 35(6):1371-8. PubMed ID: 2770115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Desferrioxamine treatment of osteomalacia caused by aluminum poisoning].
    Charhon SA; Chavassieux P; Chapuy MC; Accominotti M; Traeger J; Meunier PJ
    Presse Med; 1986 Jan; 15(2):55-9. PubMed ID: 2935857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful treatment of dialysis osteomalacia and dementia, using desferrioxamine infusions and oral 1-alpha hydroxycholecalciferol.
    Hood SA; Clark WF; Hodsman AB; Bolton CF; Cordy PE; Anderson C; Leung F
    Am J Nephrol; 1984; 4(6):369-74. PubMed ID: 6517116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined hemofiltration and desferrioxamine treatment for aluminum induced osteomalacia.
    Barré PE; Prichard S
    Int J Artif Organs; 1986 May; 9(3):167-72. PubMed ID: 3733242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Haemodialysis related osteomalacia: a staining method to demonstrate aluminium.
    Buchanan MR; Ihle BU; Dunn CM
    J Clin Pathol; 1981 Dec; 34(12):1352-4. PubMed ID: 6173400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypercalcaemic osteomalacia due to aluminium toxicity.
    Boyce BF; Fell GS; Elder HY; Junor BJ; Elliot HL; Beastall G; Fogelman I; Boyle IT
    Lancet; 1982 Nov; 2(8306):1009-13. PubMed ID: 6127501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Osteomalacia induced by aluminum in a patient under chronic hemodialysis: successful treatment with desferrioxamine].
    Espinoza O; Gehrung E; Roessler E; Katz E; Pérez A; Delmastro J
    Rev Med Chil; 1986 Sep; 114(9):867-71. PubMed ID: 3575972
    [No Abstract]   [Full Text] [Related]  

  • 20. Hypercalcaemic osteomalacia and encephalopathy due to aluminium intoxication in haemodialysis patients. Clinical aspects and treatment with desferrioxamine.
    Mudde AH; Roodvoets AP; Van Groningen K
    Neth J Med; 1985; 28(1):6-11. PubMed ID: 3974771
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.